ft596
Cell therapyexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 31, 2020 (NCT04245722)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05934097 | Phase 1 | Dec 31, 2022 | Fate Therapeutics |
| NCT04555811 | Phase 1 | Sep 22, 2020 | University of Minnesota |
| NCT04245722 | Phase 1 | Jan 31, 2020 | Fate Therapeutics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Fate Therapeutics | For profit | 2 | 2 | 1 | 2020 |
| University of Minnesota | Academic/Hospital | 1 | 1 | 1 | 2020 |
2 organizations
Page 1 / 1